SpineGuard and OrthoPediatrics announce national distribution agreement for US pediatric institutions
PARIS, SAN FRANCISCO and WARSAW, March 17, 2016 – SpineGuard (FR0011464452 – ALSGD), an innovative company that designs, develops and markets disposable medical devices intended to make spine surgery safer, announced today a national stocking distribution agreement with OrthoPediatrics for the exclusive commercialization of its PediGuard probes in pediatric institutions in the US. OrthoPediatrics is the only medical device company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market in order to improve the lives of children with various orthopedic pathologies.
“We are delighted to partner with OrthoPediatrics for the distribution of our smart drilling devices. I have been very impressed with the quality of their management team and their commitment to the cause of improving the lives of children with orthopedic conditions,” said Pierre Jérôme, CEO and Co-founder of SpineGuard. “This partnership will enhance our exposure into US pediatric institutions where we believe our Dynamic Surgical Guidance technology can bring great clinical value.”
Mark Throdahl, President and CEO of OrthoPediatrics, said, “OrthoPediatrics’ goal is to advance the field of pediatric orthopedics with the broadest and most innovative product line in our industry. PediGuard probes are a valuable addition to our complex spine offering, addressing the safety needs of both patients and surgeons. We are pleased to partner with SpineGuard on the application of this innovative technology to pediatric orthopedic surgery.”
Next financial press release: Full Year 2015 financial results, on March 23, 2016.
About SpineGuard®
Co-founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard’s mission is to make spine surgery safer. Its primary objective is to establish its proprietary DSG™ (Dynamic Surgical Guidance) technology as the global standard of surgical care, initially for safer screw placement in spine surgery and then in other surgeries. PediGuard®, the first device designed using DSG was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. It is the world’s first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. Over 40,000 surgical procedures have been performed worldwide with PediGuard. Numerous studies published in peer-reviewed medical and scientific journals have demonstrated the multiple benefits that PediGuard delivers to patients, surgical staff and hospitals. In 2015, SpineGuard started to expand the applications of DSG into pedicle screws through partnerships with innovative surgical companies in France and the US. SpineGuard has offices in San Francisco and Paris. For further information, visit www.spineguard.com.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is the only orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market in order to improve the lives of children with orthopedic conditions. OP currently markets 17 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma and deformity, complex spine, and ACL reconstruction procedures. OP also has the only global sales organization focused exclusively on pediatric orthopedics and distributes its products to 29 countries outside the USA. For more information, contact Mallory Trusty at 574-267-0825.
Disclaimer
The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.
Contacts
SpineGuard
Pierre Jérôme Manuel Lanfossi
CEO Chief Financial Officer
Tel: +33 (0)1 45 18 45 19 m.lanfossi@spineguard.com
Europe/NewCap.
Investor relations & Financial communication
Florent Alba / Pierre Laurent Tel: +33 (0)1 44 71 94 94
Media Relations/US
Ronald Trahan, APR, Ronald Trahan Associates Inc.
+1-508-359-4005, x108
